Blog Archives

Blog

Common Clinical Trial Disclosure Challenges & Potential Solutions

Pharmaceutical companies are being required to be more transparent through the timely disclosure of more…

CertaraFebruary 24, 2023

Blog

Artificial Intelligence: What is it & how can it accelerate rare disease drug development?

Large & complex information streams present opportunities for the AI data scientist to aid in…

CertaraFebruary 3, 2023

Blog

Will the Inflation Reduction Act Impact Drug Development Decisions?

The short answer is yes. In fact, passage of the Inflation Reduction Act (H.R. 5376)…

CertaraJanuary 27, 2023

Blog

Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis

These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…

CertaraJanuary 20, 2023

Blog

New FDA Validator Rules V1.6 Explained

In this blog, we explore what you need to know about the update to the…

CertaraJanuary 12, 2023

Blog

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

CertaraDecember 21, 2022

Blog

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

CertaraDecember 16, 2022

Blog

Tips & Tricks for Data Management in Phoenix WinNonlin

Learn some tips & tricks for the Data Wizard, a data management tool in Phoenix,…

CertaraNovember 18, 2022

Blog

Tips to Use Phoenix WinNonlin More Efficiently

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…

CertaraNovember 7, 2022

Blog

The Role of PBPK Modeling & Simulation in Infants & Neonates

Many factors make it challenging to obtain adequate pediatric samples for use in drug development…

CertaraNovember 4, 2022

Blog

Common Clinical Trial Disclosure Challenges & Potential Solutions

Artificial Intelligence: What is it & how can it accelerate rare disease drug development?

Will the Inflation Reduction Act Impact Drug Development Decisions?

Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis

New FDA Validator Rules V1.6 Explained

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Tips & Tricks for Data Management in Phoenix WinNonlin

Tips to Use Phoenix WinNonlin More Efficiently

The Role of PBPK Modeling & Simulation in Infants & Neonates

Newsletter sign up

Quick links

Solutions

Contact